Treatment regimens involving the monoclonal anti-CD20 antibody rituximab are the standard of care for patients with CD20-positive non-Hodgkin lymphoma (NHL). It has conventionally been given by intravenous (IV) infusion, which requires intermittent patient monitoring during administration. A subcutaneous (SC) formulation is also available for the treatment of NHL, which takes less time to administer and could simplify treatment. With the newer formulation available, there is an ongoing need for education and understanding from the patient’s and the healthcare professional’s perspective. The authors review their personal experience of rituximab IV and SC formulations together with data on their safety, and provide an overview of the use of SC formulation in daily nursing practice.
Cancer Nursing Practice. 14, 8, 29-37. doi: 10.7748/cnp.14.8.29.s22Correspondence
This article has been subject to double-blind review and checked using antiplagiarism softwareConflict of interest
The production cost and support for third-party writing assistance for this manuscript were provided by F Hoffmann-La Roche Ltd who have checked it for factual accuracy, with editorial control remaining with the journal at all times
Received: 20 March 2015
Accepted: 03 August 2015
Alternatively, you can purchase access to this article for the next seven days. Buy now